Arbutus Biopharma Corp. (ABUS) Receives Sell Rating from Chardan Capital
ABUS has been the subject of a number of other reports. William Blair reissued an outperform rating on shares of Arbutus Biopharma Corp. in a report on Sunday, August 21st. Zacks Investment Research raised Arbutus Biopharma Corp. from a sell rating to a hold rating in a report on Wednesday, August 24th. Wedbush reissued an outperform rating and issued a $20.00 target price (up from $13.00) on shares of Arbutus Biopharma Corp. in a report on Friday, August 5th. Finally, Leerink Swann cut Arbutus Biopharma Corp. from an outperform rating to a market perform rating and set a $5.00 target price for the company. in a report on Friday, August 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. The company has a consensus rating of Hold and a consensus target price of $7.63.
Arbutus Biopharma Corp. (NASDAQ:ABUS) traded down 11.57% during mid-day trading on Friday, hitting $3.44. The stock had a trading volume of 860,300 shares. Arbutus Biopharma Corp. has a 1-year low of $2.72 and a 1-year high of $6.74. The firm’s market cap is $188.50 million. The stock has a 50 day moving average of $3.79 and a 200-day moving average of $4.06.
Arbutus Biopharma Corp. (NASDAQ:ABUS) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by $0.36. Arbutus Biopharma Corp. had a negative return on equity of 8.87% and a negative net margin of 1,017.01%. Analysts predict that Arbutus Biopharma Corp. will post ($3.35) EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the company. Bank of Montreal Can acquired a new stake in Arbutus Biopharma Corp. during the second quarter worth approximately $2,822,000. I.G. Investment Management LTD. purchased a new position in shares of Arbutus Biopharma Corp. during the second quarter worth approximately $870,000. K2 Principal Fund L.P. raised its position in shares of Arbutus Biopharma Corp. by 113.6% in the second quarter. K2 Principal Fund L.P. now owns 63,550 shares of the biopharmaceutical company’s stock worth $221,000 after buying an additional 33,796 shares during the last quarter. Suffolk Capital Management LLC raised its position in shares of Arbutus Biopharma Corp. by 7.6% in the second quarter. Suffolk Capital Management LLC now owns 441,915 shares of the biopharmaceutical company’s stock worth $1,538,000 after buying an additional 31,023 shares during the last quarter. Finally, AXA raised its position in shares of Arbutus Biopharma Corp. by 1.4% in the second quarter. AXA now owns 792,358 shares of the biopharmaceutical company’s stock worth $2,757,000 after buying an additional 11,062 shares during the last quarter. Institutional investors and hedge funds own 31.87% of the company’s stock.
About Arbutus Biopharma Corp.
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Stock Ratings for Arbutus Biopharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corp. and related stocks with our FREE daily email newsletter.